The overall goal of this project is to determine the relationships among the clinical, cognitive, imaging (MRI and PET), genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNI3 continues the currently funded AD Neuroimaging Initiative (ADNI2), a public/private collaboration between academia and industry to study biomarkers of AD as well as a previously funded ADNI1 and Grand Opportunities (GO) grants which supplemented ADNI goals and activities. ADNI will inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios.
April 2017 to July 2017
This project led by: Sterling Johnson, PhD